Male circumcision reduces penile high-risk human papillomavirus viral load in a randomised clinical trial in Rakai, Uganda

Sexually Transmitted Infections

Volumn 89, Issue 3, 2013, Pages 262-266

  Wilson, Lauren E ^a   Gravitt, Patti ^a   Tobian, Aaron A R ^a,b   Kigozi, Godfrey ^c   Serwadda, David ^c,d   Nalugoda, Fred ^c   Watya, Stephen ^d   Wawer, Maria J ^a,c   Gray, Ronald H ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CIRCUMCISION; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; UGANDA; VIRUS LOAD; VIRUS SHEDDING; WART VIRUS;

ADOLESCENT; ADULT; CIRCUMCISION, MALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE DISEASES; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 84878207792     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2012-050633     Document Type: Article

References (22)

1. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9. (Pubitemid 46962343)
2. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204. (Pubitemid 40450709)
3. Tobian A, Gray R, Quinn T. Male circumcision prevents acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med 2010;164:78-84.
4. Tobian A, Gray R. The medical benefits of male circumcision. JAMA 2011;306:1479-80.
5. Bailey R, Moses S, Parker C, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-56. (Pubitemid 46281312)
6. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005;2:e298.
7. Gray R, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai Uganda: a randomised trial. Lancet 2007;369:657-66.
8. Tobian A, Serwadda D, Quinn T, et al. Male circumcision for the prevention of HSV-2, HPV infections, syphilis. N Engl J Med 2009;360:1298-309.
9. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of the randomized clinical trial conducted in Orange Farm, South Africa. J Infect Dis 2009;199:14-19.
10. Serwadda D, Wawer M, Makumbi F, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis 2010;201:1463-9.
11. Gray R, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010;201:1455-62.
12. Tobian A, Kong X, Gravitt P, et al. Male circumcision and anatomic sites of penile high-risk human papillomavirus in Rakai, Uganda. Int J Cancer 2011;129:2970-5.
13. Wawer M, Tobian A, Kigozi G, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomized trial in Rakai, Uganda. Lancet 2011;377:209-18.
14. Park J, Lee K, Dong S, et al. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol 2008;108:549-54.
15. Bleeker M, Hogewoning C, Berkhof J, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005;41:612-20. (Pubitemid 41170348)
16. Gravitt P, Peyton C, Apple R, et al. Genotyping of 27 human papillomavirus types by using L1 consensus PCR product by a single- hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-7. (Pubitemid 28429431)
17. Wentzensen N, Gravitt P, Long R, et al. Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens. J Clin Microbiol 2012;50:1564-70.
18. Gravitt P, Schiffman M, Solomon D, et al. A comparison of Linear Array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL Triage Study. Cancer Epidemiol Biomarkers Prev 2008;17:1248-54.
19. Gravitt P, Peyton C, Wheeler C, et al. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 2003;112:23-33. (Pubitemid 37338255)
20. Gillison M, D'Sousza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-40.
21. Marks M, Gupta S, Liaw K, et al. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array© using HPV52-specific TaqMan© E6/E7 quantitative real-time PCR. J Virol Methods 2009;156:152-56.
22. Vanbuskirk K, Winer R, Hughes J, et al. Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis 2011;38:1074-81.